Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The data show that subcutaneous administration of RUC-4 resulted in a potent, rapid, and sustained platelet inhibition effect that largely resolved after two hours.
Lead Product(s): RUC-4
Therapeutic Area: Cardiology/Vascular Diseases Product Name: RUC-4
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020